Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome. Pacritinib (Vonjo) is a kinase inhibitor (JAK2, FLT3) that is approved to treat adults with intermediate or high-risk myelofibrosis https://t.co/V7duJPyJpG https://t.co/Dn5DgeaX7N

Osteoarthritis, Obesity and GLP-1s https://t.co/SGnWksQBpT https://t.co/ILP3weScxh

Leeds study of 44 patients idiopathic inflamm myopathy (IIM) pts Rx w/ rituximab showed a 70% response 4-6 mos post RTX. Responders had higher TIS (50·0 vs 17·5). Using highly sensitive flow cytometry, @ 2 wks responders had lower #s memory B cells & Plasmablasts. Is there a role https://t.co/JDvVZ1KEIY

Music and Pain Relief A new scoping review in Pain Reports by Bradt et al., examines the effect of MBIs on pain management. While its efficacy is well established, how or why music relieves pain has never been fully explained. This systematic review is based on 663 records and https://t.co/0FJgzWSoOB

EBR Journal Club: Dapirolizumab Pegol in SLE (PHOENYCS GO) The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk https://t.co/Pi45T99oJm

True or False: In a Leeds study of idiopathic inflammatory myopathy patients treated with rituximab, responders had lower memory B cells and plasmablasts at 2 weeks. See if you got it right in this week's RheumIQ quiz at https://t.co/UaXqHKWizt. https://t.co/zRJOMeLn8M

Obesity isn’t just a comorbidity—it can influence inflammation, disease activity, and treatment response. Join our second Tuesday Night Rheumatology webinar this month as leading experts explore the biology of fat and its impact on rheumatic disease. Register: https://t.co/0EqO9g1sHn

QD Clinic: Weight Loss Changed the Course of RA Dr. Bella Mehta, New York, presents this case which highlights that obesity may be a target for disease modification in rheumatoid arthritis, as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026. https://t.co/KNNS0cHmA4

AI Diagnosing Rheumatic Disease? Prof. Valmed, a large language model (LLM) cleared by European regulators for medical diagnosis, outperformed human physicians for diagnosing rheumatologic conditions in terms of speed but not accuracy, a randomized trial showed. https://t.co/WVKlRGHFL1

Dutch single center study of ANCA tests (n 5518) betw 2012-2023; 286 (5.2%) were positive: 63% did not have AAV. ANCA+ Non-AAV pts had other CTD, neoplasia, infxn, or used specific drugs. IIF and ELISA 1st test - good negative predictive values. Performing a second test increased https://t.co/0oAhOg10VL

The 1980s quietly rewired rheumatology. Methotrexate became the anchor DMARD. APS emerged as a distinct clinical syndrome. SLE classification was standardized. Cytokine biology began pointing toward the biologic era. A decade that moved rheumatology from symptom control toward https://t.co/9NUXorQDTG

Dr John Stone grand rounds Kroc lecture #wustlRheum. Pearls: -IgG4RD can manifest as a variable vasculitis -Men have worse disease -Histology will not show necrosis or neutrophils -IgG4 levels will rise as the disease progress (>5X) -Rx with B cell therapy @alhkim @RheumNow https://t.co/GUw348OrrA

FDA Grants Fast Track Designation to treprostinil inhalation powder (Yutrepia - currently FDA approved to tx Pulm HTN) for the Treatment of Raynaud’s Phenomenon assoc w/ Systemic Sclerosis. A Phase 2a RE-WARM dose-finding study will begin October 2026. https://t.co/x4X1Ld1egZ https://t.co/GsZ9LXJjre

Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome. Pacritinib (Vonjo) is a kinase inhibitor (JAK2, FLT3) that is approved to treat adults with intermediate or high-risk myelofibrosis https://t.co/V7duJPyJpG https://t.co/N9rg30EA4W